A Randomised Controlled Trial (RCT) Of Azithromycin Versus Doxycycline For The Treatment Of Rectal Chlamydia Infection In Men Who Have Sex With Men.
Funder
National Health and Medical Research Council
Funding Amount
$797,906.00
Summary
Rectal chlamydia is very common among gay men; it can exist for long periods without symptoms leading to ongoing transmission. Azithromycin (1 gram single dose) or 7 days doxycycline (100mg twice daily) are the two recommended treatments globally. But, there is concern about rectal chlamydia treatment with reports of up to 22% failure following azithromycin. We will conduct a randomised trial to compare these treatments for rectal chlamydia and determine which drug works better.
Genetics and evolution of Shigella O antigens. We use genome scale sequencing techniques to sequence 26 O-antigen gene clusters from Shigella. With the seven already known, this will give sequences for every O-antigen of Shigella. This will be the first time that such set is fully sequenced. Shigella are human specific pathogens, have emerged with the evolution of humans. O-antigens are important for their life and pathogenicity. This project will greatly extend our knowledge of the genetic basi ....Genetics and evolution of Shigella O antigens. We use genome scale sequencing techniques to sequence 26 O-antigen gene clusters from Shigella. With the seven already known, this will give sequences for every O-antigen of Shigella. This will be the first time that such set is fully sequenced. Shigella are human specific pathogens, have emerged with the evolution of humans. O-antigens are important for their life and pathogenicity. This project will greatly extend our knowledge of the genetic basis and evolution of this important polymorphism. O-antigens are used for typing Shigella and also elicit strong immunity. The molecular data will help establish DNA based typing and vaccine development.Read moreRead less
Industrial Transformation Training Centres - Grant ID: IC170100035
Funder
Australian Research Council
Funding Amount
$4,743,710.00
Summary
ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to devel ....ARC Training Centre for Innovation in Biomedical Imaging Technology. The ARC Training Centre for Innovation in Biomedical Imaging Technology expects to train 20 industry-ready innovation scientists who will undertake industry-driven research in the development and application of novel diagnostics, therapeutics and theranostics. They will inform changes in regulatory policy that support industry growth. The Centre will build multidisciplinary links between researchers and within industry to develop ‘smart’ probes and ‘smart’ scanning, harnessing the digital revolution for better, cost effective diagnostic imaging and improved health outcomes.Read moreRead less
Electric field induced surface attachment and detachment of proteins. Microarrays are revolutionising the diagnosis of disease by enabling large amounts of data on genetics and protein expression to be obtained from one sample. Biosensors for diseases and toxins rely on the same mechanism, namely attachment of biological macromolecules to a surface. We propose a new method for controlling the attachment by micromachining an electrode system to apply an electric field to chosen sites. Ultimately ....Electric field induced surface attachment and detachment of proteins. Microarrays are revolutionising the diagnosis of disease by enabling large amounts of data on genetics and protein expression to be obtained from one sample. Biosensors for diseases and toxins rely on the same mechanism, namely attachment of biological macromolecules to a surface. We propose a new method for controlling the attachment by micromachining an electrode system to apply an electric field to chosen sites. Ultimately microelectronic engineering methods will be used. This will give control over the attachment process with potential benefits of orienting attaching molecules, minimising non-specific attachment and enriching diagnostics by enabling interrogation of the force of attachment.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH150100028
Funder
Australian Research Council
Funding Amount
$3,708,510.00
Summary
ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecu ....ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. ARC Research Hub for Integrated Device for End-user Analysis at Low-levels. This hub aims to improve detection of biological materials by building a portable device for rapid, time-critical detection of low-abundance molecular and cellular analytes. It is expected that the resulting technologies would be used at medical points of care, ordinary workplaces and centres of activity to test for tiny levels of targeted molecules. The initial focus would be early diagnosis of disease and point-of-care drug testing for humans and animals, but the technology platform could be used to sample food and environmental toxins. The hub expects these disruptive technologies will make Australian biotechnology, diagnostics, veterinary, agribusiness and manufacturing firms globally competitive.Read moreRead less
Industrial Transformation Research Hubs - Grant ID: IH220100017
Funder
Australian Research Council
Funding Amount
$4,808,669.00
Summary
ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The progra ....ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals. Radiopharmaceuticals are emerging as next generation medical technologies for addressing complex health challenges, and their manufacture offers significant economic benefit to Australia. The ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals (AMTAR) aims to establish a manufacturing platform for new medical technologies combining innovations in biotechnology and pharmaceutical science. The program addresses industry-led challenges for translation of biologics as molecular radiopharmaceuticals, building capacity in biomanufacturing, radiobiology and radiochemistry. The program establishes a dedicated manufacturing pipeline, future-proofing production and securing supply chain of next generation medical technologies.Read moreRead less
An International Clinical Trial To Evaluate New Therapies To Improve Survival Of Children With Relapsed Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$1,567,500.00
Summary
Children who relapse with childhood leukaemia have only a 50% chance of being alive after 5 years. We will participate in a new international trial involving most European and all Australian and New Zealand childhood oncology centres, to test the effectiveness of promising new treatments and to perform biological studies which should enable doctors in future to pick the best treatment for each of these patients.
Miniaturised biosensors with high selectivity . This project aims to develop a technological platform for the fabrication of miniaturised and flexible sensors that enable the quantitative detection of important bioactive compounds such as fatty acids and biogenic amines. By utilising multi-enzymatic reactions in solid phase and engineering task-specific inks, chemiresistive sensors will be printed seamlessly as a whole. The sensors will respond to complex target biomolecules via a series of enzy ....Miniaturised biosensors with high selectivity . This project aims to develop a technological platform for the fabrication of miniaturised and flexible sensors that enable the quantitative detection of important bioactive compounds such as fatty acids and biogenic amines. By utilising multi-enzymatic reactions in solid phase and engineering task-specific inks, chemiresistive sensors will be printed seamlessly as a whole. The sensors will respond to complex target biomolecules via a series of enzymatic reactions through which the analyte will convert to much simpler, reactive and hence measurable molecules. This project will enable to design miniaturised sensors for point-of-care detection of biomolecules that cannot be yet evaluated by the end users.Read moreRead less
Molecular approaches to solving current and emerging problems in the epidemiology and diagnosis of Marek's disease in Australia. Marek's disease (MD) is a ubiquitous viral disease of chickens that is currently controlled in meat chickens by blanket vaccination of all chickens. However, as has happened overseas, the efficacy of the HVT vaccine being used in Australia is breaking down resulting in subclinical and clinical losses due to MD. To assist industry deal with this situation we propose to ....Molecular approaches to solving current and emerging problems in the epidemiology and diagnosis of Marek's disease in Australia. Marek's disease (MD) is a ubiquitous viral disease of chickens that is currently controlled in meat chickens by blanket vaccination of all chickens. However, as has happened overseas, the efficacy of the HVT vaccine being used in Australia is breaking down resulting in subclinical and clinical losses due to MD. To assist industry deal with this situation we propose to develop novel molecular methods for the quantification of Marek's disease viruses (MDV) in the host and the environment, to use these methods to design effective early monitoring systems for MD in broilers that predict disease and performance outcomes, and to develop an epidemiological model that will predict the spread and severity of MD as failure of vaccinal protection progresses.Read moreRead less
Advancing hybrid imaging with magnetic resonance imaging and positron emission tomography (MRI-PET). This project aims to increase the utility, accessibility, cost-effectiveness and accuracy of magnetic resonance imaging and positron emission tomography (MRI-PET) hybrid imaging technology for brain tumour imaging. This project will develop new contrast agents, better ways of measuring their uptake including a new high sensitivity MRI-PET head coil and methods for predicting tumour progression us ....Advancing hybrid imaging with magnetic resonance imaging and positron emission tomography (MRI-PET). This project aims to increase the utility, accessibility, cost-effectiveness and accuracy of magnetic resonance imaging and positron emission tomography (MRI-PET) hybrid imaging technology for brain tumour imaging. This project will develop new contrast agents, better ways of measuring their uptake including a new high sensitivity MRI-PET head coil and methods for predicting tumour progression using imaging information.Read moreRead less